Phase 1 clears key safety hurdles; Phase 2 launch remains on track

The quarter’s financial result was essentially in line with expectations. Shattuck reported a $0.12 per-share loss, matching the published consensus of roughly a $0.12 loss. There is no revenue, as expected for a clinical-stage biotech, while the larger share count helped reduce the reported per-share loss despite higher spending. (Income Statement)

The meaningful new information is the Phase 1 readout for SL-325, not the income statement. The company reported a favorable safety profile, low-dose durability of DR3 blockade, no evidence of residual DR3 agonism, and what it describes as potentially best-in-mechanism immunogenicity. Those findings clear important development risks, but the filing provides topline claims rather than detailed patient-level efficacy data, so it does not yet establish clinical benefit. (SL-325 clinical update)

The development timeline remains intact rather than moving ahead of expectations. The Crohn’s disease Phase 2b trial is still expected to begin in the third quarter of 2026, while SL-846 toxicology data are expected at a medical conference in October. These are constructive execution updates, but they largely confirm the previously stated path rather than represent an accelerated milestone. (Recent business highlights; SL-846 program update)

Cash materially reduces near-term financing risk, although the improvement reflects capital raised rather than operating progress. Cash and short-term investments totaled approximately $208.3 million at June 30, and management says funding should extend into 2029. At the same time, research spending rose 35% year over year as the company advances toward Phase 2. (Balance Sheet; Financial Highlights; Income Statement) Net read: clinically encouraging and financially well funded, but the quarter itself was broadly expected and the decisive efficacy test remains ahead.